vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $5.0M, roughly 1.9× cbdMD, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -5.6%, a 6.3% gap on every dollar of revenue. On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -3.0%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-977.3K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 7.1%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
SSKN vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $5.0M |
| Net Profit | $58.0K | $-283.1K |
| Gross Margin | 61.8% | 59.8% |
| Operating Margin | 5.3% | -5.7% |
| Net Margin | 0.6% | -5.6% |
| Revenue YoY | -3.0% | -1.9% |
| Net Profit YoY | 101.3% | -1975.7% |
| EPS (diluted) | $0.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $5.0M | ||
| Q3 25 | $6.9M | $4.7M | ||
| Q2 25 | $7.7M | $4.6M | ||
| Q1 25 | $6.8M | $4.7M | ||
| Q4 24 | $9.6M | $5.1M | ||
| Q3 24 | $8.8M | $4.6M | ||
| Q2 24 | $8.4M | $5.2M | ||
| Q1 24 | $6.8M | $4.4M |
| Q4 25 | $58.0K | $-283.1K | ||
| Q3 25 | $-1.6M | $-680.0K | ||
| Q2 25 | $-2.6M | $-895.3K | ||
| Q1 25 | $-2.1M | $-480.8K | ||
| Q4 24 | $-4.6M | $15.1K | ||
| Q3 24 | $-2.1M | $-152.8K | ||
| Q2 24 | $-91.0K | $459.7K | ||
| Q1 24 | $-3.4M | $-3.0M |
| Q4 25 | 61.8% | 59.8% | ||
| Q3 25 | 60.4% | 58.8% | ||
| Q2 25 | 56.2% | 61.5% | ||
| Q1 25 | 53.5% | 62.3% | ||
| Q4 24 | 61.4% | 66.5% | ||
| Q3 24 | 60.1% | 53.9% | ||
| Q2 24 | 59.0% | 65.8% | ||
| Q1 24 | 45.6% | 59.0% |
| Q4 25 | 5.3% | -5.7% | ||
| Q3 25 | -16.9% | -14.5% | ||
| Q2 25 | -30.1% | -19.6% | ||
| Q1 25 | -25.0% | -10.2% | ||
| Q4 24 | -44.7% | -1.7% | ||
| Q3 24 | -18.2% | -6.9% | ||
| Q2 24 | -5.7% | -7.4% | ||
| Q1 24 | -42.7% | -35.4% |
| Q4 25 | 0.6% | -5.6% | ||
| Q3 25 | -23.4% | -14.4% | ||
| Q2 25 | -33.6% | -19.4% | ||
| Q1 25 | -31.2% | -10.1% | ||
| Q4 24 | -47.6% | 0.3% | ||
| Q3 24 | -23.6% | -3.4% | ||
| Q2 24 | -1.1% | 8.9% | ||
| Q1 24 | -49.8% | -68.8% |
| Q4 25 | $0.14 | — | ||
| Q3 25 | $-0.36 | — | ||
| Q2 25 | $-0.62 | — | ||
| Q1 25 | $-0.51 | — | ||
| Q4 24 | $-2.01 | — | ||
| Q3 24 | $-0.51 | — | ||
| Q2 24 | $-0.03 | $-0.15 | ||
| Q1 24 | $-0.10 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $3.4M |
| Total DebtLower is stronger | $15.3M | — |
| Stockholders' EquityBook value | $2.9M | $9.0M |
| Total Assets | $30.5M | $11.8M |
| Debt / EquityLower = less leverage | 5.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $3.4M | ||
| Q3 25 | $7.1M | $2.3M | ||
| Q2 25 | $6.0M | $1.1M | ||
| Q1 25 | $6.5M | $1.8M | ||
| Q4 24 | $7.3M | $2.0M | ||
| Q3 24 | $7.1M | $2.5M | ||
| Q2 24 | $5.5M | $2.4M | ||
| Q1 24 | $5.2M | $2.1M |
| Q4 25 | $15.3M | — | ||
| Q3 25 | $15.3M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $15.0M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | $2.9M | $9.0M | ||
| Q3 25 | $1.3M | $7.2M | ||
| Q2 25 | $532.0K | $6.1M | ||
| Q1 25 | $3.0M | $665.8K | ||
| Q4 24 | $5.0M | $1.8M | ||
| Q3 24 | $9.4M | $2.0M | ||
| Q2 24 | $9.5M | $3.0M | ||
| Q1 24 | $9.4M | $3.1M |
| Q4 25 | $30.5M | $11.8M | ||
| Q3 25 | $30.7M | $10.4M | ||
| Q2 25 | $29.5M | $9.9M | ||
| Q1 25 | $33.0M | $10.9M | ||
| Q4 24 | $34.9M | $11.5M | ||
| Q3 24 | $39.4M | $10.6M | ||
| Q2 24 | $38.8M | $13.8M | ||
| Q1 24 | $39.2M | $14.6M |
| Q4 25 | 5.28× | — | ||
| Q3 25 | 11.65× | — | ||
| Q2 25 | 28.20× | — | ||
| Q1 25 | 5.04× | — | ||
| Q4 24 | 3.02× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 1.59× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $-812.5K |
| Free Cash FlowOCF − Capex | $-551.0K | $-977.3K |
| FCF MarginFCF / Revenue | -5.9% | -19.5% |
| Capex IntensityCapex / Revenue | 3.4% | 3.3% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $-812.5K | ||
| Q3 25 | $-64.0K | $-240.7K | ||
| Q2 25 | $-1.9M | $-704.2K | ||
| Q1 25 | $-550.0K | $-189.5K | ||
| Q4 24 | $703.0K | $-317.9K | ||
| Q3 24 | $-302.0K | $167.4K | ||
| Q2 24 | $591.0K | $289.8K | ||
| Q1 24 | $-804.0K | $-704.1K |
| Q4 25 | $-551.0K | $-977.3K | ||
| Q3 25 | $-1.1M | $-243.6K | ||
| Q2 25 | $-2.0M | $-705.7K | ||
| Q1 25 | $-749.0K | $-205.0K | ||
| Q4 24 | $199.0K | $-482.3K | ||
| Q3 24 | $-364.0K | $157.4K | ||
| Q2 24 | $246.0K | — | ||
| Q1 24 | $-1.5M | $-708.7K |
| Q4 25 | -5.9% | -19.5% | ||
| Q3 25 | -15.6% | -5.2% | ||
| Q2 25 | -26.1% | -15.3% | ||
| Q1 25 | -11.0% | -4.3% | ||
| Q4 24 | 2.1% | -9.4% | ||
| Q3 24 | -4.1% | 3.5% | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | -22.6% | -16.2% |
| Q4 25 | 3.4% | 3.3% | ||
| Q3 25 | 14.7% | 0.1% | ||
| Q2 25 | 0.8% | 0.0% | ||
| Q1 25 | 2.9% | 0.3% | ||
| Q4 24 | 5.3% | 3.2% | ||
| Q3 24 | 0.7% | 0.2% | ||
| Q2 24 | 4.1% | 0.0% | ||
| Q1 24 | 10.7% | 0.1% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
